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Human  pluripotent  stem  cells  (hPSCs)  can  self-­renew  indefinitely,  making  them  an  
attractive   source   for   regenerative   therapies.   This   expansion   potential   has   been  
linked  with  acquisition  of  large  copy  number  variants  (CNVs)  that  provide  mutant  
cells   with   a   growth   advantage   in   culture1-­3.   However,   the   nature,   extent,   and  
functional   impact   of   other   acquired   genome   sequence   mutations   in   cultured  
hPSCs   is  not  known.  Here,  we  sequenced   the  protein-­coding  genes   (exomes)  of  
140   independent   human   embryonic   stem   cell   (hESC)   lines,   including   26   lines  
prepared  for  potential  clinical  use4.  We  then  applied  computational  strategies  for  
identifying  mutations  present  in  a  subset  of  cells5.  Though  such  mosaic  mutations  
were   generally   rare,   we   identified   five   unrelated   hESC   lines   that   carried   six  
mutations  in  the  TP53  gene  that  encodes  the  tumor  suppressor  P53.  Notably,  the  
TP53  mutations  we  observed  are  dominant  negative  and  are   the  mutations  most  
commonly  seen   in  human  cancers.  We  used  droplet  digital  PCR   to  demonstrate  
that   the   TP53   mutant   allelic   fraction   increased   with   passage   number   under  
standard   culture   conditions,   suggesting   that   P53   mutation   confers   selective  
advantage.  When  we  then  mined  published  RNA  sequencing  data  from  117  hPSC  
lines  we  observed  another  nine  TP53  mutations,  all  resulting  in  coding  changes  in  
the   DNA   binding   domain   of   P53.   Strikingly,   in   three   lines,   the   allelic   fraction  
exceeded   50%,   suggesting   additional   selective   advantage   resulting   from   loss   of  
heterozygosity   at   the   TP53   locus.   As   the   acquisition   and   favored   expansion   of  
cancer-­associated   mutations   in   hPSCs   may   go   unnoticed   during   most  
applications,  we  suggest  that  careful  genetic  characterization  of  hPSCs  and  their  
differentiated  derivatives  should  be  carried  out  prior  to  clinical  use.  
   Somatic   mutations   that   arise   during   cell   proliferation   and   are   then   subject   to  
positive  selection  are  major  causes  of  cancer  and  other  diseases6.  Acquired  mutations  
are  often  present  in  a  subset  of  cells  in  a  sample,  and  can  therefore  be  detected  in  next  
generation  sequencing  data  from  their  presence  at  allelic  fractions  less  than  50%5,7.  We  
reasoned  that  similar  analysis  of  sequencing  data  from  a  large  number  of  hESCs  might  
reveal   previously   unappreciated   mosaic   mutations   and   mutation-­driven   expansions  
acquired   during   hESC   culture   at   single-­nucleotide   resolution.   This   approach   would  
complement   previous   studies   describing   culture-­derived   chromosomal-­scale  
aneuploidies  and  megabase-­scale  CNVs  in  hPSCs1,8,9.  
To  this  end,  we  sought  to  collect  and  perform  whole  exome  sequencing  (WES)  of  
hESC   lines   that   were   derived   under   appropriate   informed   consent   and   were   readily  
available   for   distribution   (Fig.   1a).   We   therefore   turned   to   the   registry   of   hESC   lines  
maintained   by   the   US   National   Institutes   of   Health   (NIH)   (Fig.   1b)   and   were   able   to  
obtain,   bank,   and   sequence   114   independent   hESC   lines  with  minimal   restrictions   on  
use  (Fig.  1c-­e).  We  selected  cell  lines  at  low  to  moderate  passage  numbers  (mean  P18,  
range  P3-­P37)  and  cultured  them  in  a  common  set  of  growth  conditions  for  an  average  
of  2.7  ±  0.7   (±  STD)  passages   (range  2-­6  passages)  prior   to  banking  and  sequencing  
(Fig.  1f,g).  This  minimal  time  in  culture  ensured  that  at  the  time  of  sequencing,  cell  lines  
were  at  similar  densities  and  growth  rates  and  were  broadly  representative  of  those  we  
received.  Since  hESC-­derived  differentiated  cells  are  currently  being  studied   in  clinical  
trials   for   their  safety  and  utility   in  a  range  of  diseases  such  as  macular  degeneration10,  
we   also   sequenced   genomic   DNA   samples   isolated   directly   from   an   additional   26  
independent   hESC   lines   that   had   been   prepared   under   good   manufacturing   practice  
(GMP)   conditions   for   potential   clinical   use   (Fig.   1c,e,g).   We   sequenced   the   whole  
exomes  of  these  140  hESC  lines  from  19  institutions  to  a  mean  read  depth  of  79.7  ±  0.1  
(±  SEM)  (range  57  for  UM4-­6  to  115  for  UM78-­2)  (Fig.  1h).  Further  details  on  cell   lines  
acquisition  and  selection  can  be  found  in  Table  S1  and  Supplementary  Methods.    
To   identify   potentially   acquired   mutations,   we   examined   the   number   of  
sequencing   reads   at   high-­quality   and   high-­coverage   heterozygous   sites   across   the  
exome.   We   observed   that   the   allelic   fractions   for   most   variants   followed   a   binomial  
distribution,   reflecting   statistical   sampling   around   the   50%   level   expected   of   inherited  
alleles   (Fig.   2a),   as   well   as   a   much   smaller   set   of   sites   where   variant   alleles   were  
present  at  lower  fractions  (Fig.  2a,b).  We  applied  a  statistical  test  to  identify  variants  for  
which  the  observed  allelic  fractions  were  unlikely  (P<0.01  by  binomial  test)  to  have  been  
generated  by  random  sampling  of  two  equally-­present  alleles.  We  found  263  candidate  
mosaic  variants,  of  which  28  were  predicted  to  have  a  damaging  or  disruptive  effect  on  
gene  function  (Table  S2).  
The   only   gene   affected   by   more   than   one   such   mutation   was   the   tumor  
suppressor   gene   TP53.   TP53   was   affected   by   six   of   the   28   mutations,   found   in   five  
unrelated   hESC   lines   (Table   S3),   and   one   GMP-­prepared   cell   line   (MShef10)   which  
carried  two  distinct  TP53  variants  (G245S  and  R248W).  These  six  missense  mutations,  
while   rare   (<0.01%)   in   the  general  population11   (Fig.  2c),  mapped  precisely   to   the   four  
codons  most  frequently  disrupted  in  human  cancer  (Fig.  2d,  Table  S3)12-­14.  Since  P53  is  
mutated  in  approximately  50%  of  tumors15,  coding  mutations  in  these  four  residues  are  
associated  with  a  substantial  fraction  of  human  cancer  disease  burden.  Each  of  the  six  
mutations  involved  a  cytosine  residue  of  a  CpG  dinucleotide  and  may  therefore  involve  a  
highly  mutable  site16.    
On  a  crystal   structure  of   the  human  P53  protein  complexed  with  DNA,  each  of  
the   mutations   mapped   to   the   DNA-­binding   domain   of   P5317   (Fig.   2e,f).   Mutations   at  
these  positions  are  strongly  associated  with  cancer  and  are  known  to  act  in  a  dominant  
negative   fashion   to   substantially   diminish   P53’s   regulation   of   apoptosis,   cell   cycle  
progression,   and   genomic   stability18.   Individuals   with   germ-­line   mutations   at   these  
residues  develop  Li-­Fraumeni  syndrome,  an  autosomal  dominant  disease  with  a  lifetime  
cancer   risk   of   nearly   100%19.   In   these   patients,   tumors   can   arise   at   any   age   and   can  
affect  most   tissues,   including   the   brain,   bones,   lung,   skin,   soft   tissues,   adrenal   gland,  
colon,  stomach,  and  blood20.    
To   independently   test   the  hypothesis   that   the   inactivating  TP53  mutations  were  
acquired   during   cell   culture,   we   developed   droplet   digital   PCR   (ddPCR)   assays   to  
digitally  count   the  abundance  of  each  allele  at   the   four  TP53  mutation  sites   (Fig.  3a,b,  
Table  S4).  Analysis  of  genomic  DNA  derived  from  the  140  hESC  lines  confirmed  that  all  
six  mutations  identified  by  WES  were  indeed  mosaic,  with  allelic  factions  ranging  from  7-­
40%,  suggesting  their  presence  in  14-­80%  of  cells  in  culture  (Fig.  3c).  We  did  not  identify  
additional   cell   lines   carrying  mutations   at   these   positions,   suggesting   they  were   either  
absent   or   present   at   allelic   fractions   below   the   sensitivity   of   the   assay   (approximately  
0.1%)21.   These   findings   demonstrate   that   each   of   the   TP53   mutations   identified   in  
hESCs  was  an  acquired  mutation  and  that  cells  with  the  mutation  had  come  to  represent  
a  significant  fraction  of  all  cells.  
We  next  asked  whether  the  cells  harboring  these  TP53  mutations  expanded  their  
representation  within  the  hESC  population  across  passages.  To  this  end,  we  re-­obtained  
early  passage  vials  for  hESC  lines  that  were  mosaic  for  TP53  mutations  (CHB11  at  P22,  
and  WA26   at   P13),   thawed   a   fresh   vial   of   ESI035   at   P36,   and   analyzed   the   genomic  
DNA  from  the  frozen  vial  and  at  each  subsequent  passage  to  test  for  changes  in  mutant  
allelic   fraction.   In   each   of   the   three   hESC   lines,   TP53   mutant   alleles   increased   in  
representation  at  each  analyzed  passage  (Fig.  3d)  in  all  but  one  experiment,  suggesting  
these   mutations   conferred   a   strong   selective   advantage   (approximately   1.9-­
fold/passage)  under  standard  hESC  culture  conditions   (Fig.  3e,  Fig.  S1,  Table  S5).  To  
confirm  that  this  selective  advantage  was  conferred  by  TP53  mutations  and  not  by  CNVs  
at  Chr20q11.211-­3,  we  analyzed  all  140  hESC  lines  by  SNP  arrays  and  found  that  none  
of   the   lines   carrying   TP53   mutations   also   carried   the   Chr20q   CNV   (Table   S6).   Our  
overall  results  are  consistent  with  a  model  in  which  positive  selective  pressure  for  clonal  
expansion   of   mutations   that   inactivate   P53   are   present   during   the   routine   culture   of  
hPSCs.   Indeed,   it   has  previously   been   reported   that   loss  of  P53  activity   facilitates   the  
reprogramming   of   somatic   cells   to   pluripotency22,23   and   promotes   hPSC   survival   and  
proliferation24,  suggesting  a  prominent   role   for  P53   in   regulating  self-­renewal   in  hPSCs  
(Fig.  3e).    
To   test   the   reproducibility  of  our  observations  and   to  explore   the  effects  of  P53  
mutations  in  additional  contexts,  we  screened  for  TP53  mutations  in  publically  available  
RNA  sequencing  data   from  251  hPSC  samples   in  57  published  studies,  corresponding  
to  13  hESC  and  104  hiPSC  lines  (Fig.  4a-­c,  Table  S7).  The  relatively  high  expression  of  
TP53   in  stem  cells  provided  sufficient   read  depth   for  allelic  counting  and  allowed  us   to  
identify  nine   instances  of  eight  distinct  point  mutations   in  TP53,   three  of  which  we  had  
independently   seen   by  WES.   Like   the   mutations   ascertained   by  WES,   each   of   these  
eight  mutations  led  to  missense  substitutions  in  the  DNA-­binding  domain  of  P53  (Fig.  4d-­
f,   Table   S3,   Fig.   S2).   When   we   considered   both   WES   and   RNAseq   data   sets,   we  
identified  four  codons  that  were  recurrently  mutated  in  hPSCs:  R181,  G245,  R248,  and  
R273.  Notably,  we   identified   four  distinct  TP53  mutations   in   the  commonly  used  WA09  
(H9)   hESC   line   grown   in   different   laboratories   (P151S,   R181H,   R248Q,   and   R267W)  
indicating  that  the  mutations  arose  during  cell  culture  (Fig.  4h).    
Of  the  15  instances  of  TP53  mutations  observed  by  either  WES  or  RNAseq,  the  
percentage  of  mutant  reads  suggested  that  10  were  mosaic  and  that  three  had  reached  
fixation  (50%  of  allelic  fraction).  Surprisingly,  two  cell   lines,  WA09  (R248Q)  and  WIBR3  
(H193R)   had   80%   ±   3%   and   100%   mutant   reads,   respectively   (Table   S3).   These  
findings  were   consistent  with   the   excess   allelic   fraction   observed   during   the   culture   of  
WA26   (Fig.   3d)   and   suggested   the   presence   of   additional   mutational   mechanisms  
affecting  mutant  TP53  allelic  fraction.  Indeed,  we  observed  loss  of  heterozygosity  (LOH)  
of  a   large   telomeric  domain   including   the  TP53   locus  along  chromosome  17   (Fig.  S3).  
that  was  essentially  complete  in  a  gene-­targeted  derivative  of  WIBR3  (Fig.  4i),  and  was  
partial  in  WA09,  consistent  with  the  observed  high  fraction  (80%)  of  mutant  TP53  reads.  
These   results   suggest   that   follow-­on   LOH   after   an   initial   TP53   point   mutation   likely  
confers  additional  selective  advantage.    
We  next  asked  if  TP53  mutations  might  affect  cell  differentiation  or  might  confer  
selective   advantage   or   disadvantage   in   differentiated   cells.   To   this   end,   we   examined  
studies   for   which   there   was   RNA   sequencing   data   for   both   hESCs   and   their  
differentiated   progeny.   Cell   lines   with   substantial   factions   of   TP53   mutant   cells   could  
readily  form  teratomas,  gut  epithelial  cells25  (Fig.  4i),  neuroepithelial  cells26  (Fig.  4j),  and  
pancreatic   polyhormonal   cells27   (Fig.   4k).   Notably,   a   hESC   line   harboring   a   mosaic  
G245C  mutation  expanded  its  mutant  allelic  fraction  over  the  course  of  differentiation27,  
suggesting  a  continued  selective  advantage  in  differentiating  mutant  cells.    
   Together,  our  analyses  indicate  that  researchers  have  unknowingly  and  routinely  
used   hPSCs   that   harbor   cancer-­related   missense   mutations   in   TP53,   sometimes  
accompanied  with  LOH.  These  findings  have  practical  implications  for  the  use  of  hESCs  
in   disease   modeling   and   transplantation   medicine.   The   fact   that   we   observed   TP53  
mutations   among   both   hESC   and   hiPSCs   cultured   with   a   wide   variety   of   media,  
substrates,   and   passaging   methods   (Fig.   S4)   suggests   that   new   culture   conditions  
should   be   explored   to   reduce   the   selective   pressure   for   TP53   mutations   during   cell  
culture.  We  also   suggest   that   hPSCs  should   be   regularly   subjected   to   genetic   testing,  
particularly   before   and   after   stressful   interventions   such   as   gene   editing   or   single-­cell  
cloning  that  force  hPSC  populations  through  bottlenecks  (Fig.  4l,m).  Our  specific  findings  
here   suggest   that   the   P53   pathway   should   be   an   immediate   focus   for   these   genetic  
tests.  However,   a   comprehensive  ascertainment  of   the   culture-­acquired  mutations   that  
repeatedly   occur   due   to   selective   pressures   will   require   the   analysis   of   still-­larger  
collections  of  stem  cell  lines  by  both  exome  and  whole  genome  sequencing.  
Our   findings   also   demonstrate   that   sequencing   tests   provide   an   opportunity   to  
detect   differentiated   cell   preparations   produced   from   hPSCs   that   harbor   mutations,  
which   could   prove   harmful   after   transplantation.   The   implementation   of   these   exome  
sequencing   procedures   during   the   production   of   cell   therapies   from   hPSCs   would   be  
likely   to   increase   their  safety   for   therapeutic  use   in  conditions  ranging   from  diabetes   to  
Parkinson’s  disease.  In  support  of  this  notion,  clinical  trials  with  hPSC-­derived  materials  
have   recently   been   halted   due   to   the   discovery   of   undisclosed   mutations28,   but   have  
since  resumed.  We  suggest   that  hPSCs  and  their  derivatives  be  subjected  to  genome-­
wide   analyses   at   several   key   steps:   during   initial   cell   line   selection,   as   part   of   the  
characterization  of  a  master  bank  of  hPSCs,  and  as  an  end-­stage  release  criterion  prior  
to   the   transplantation  of   the  hPSC-­derived  cellular  product.   Importantly,  although  TP53  
mutations  recurred  at  detectable   fractions   in  several  cell   lines,  most   lines  (~95%)  were  
free   of   detectable   TP53   mutations   despite   having   spent   extensive   time   in   culture.  
Regenerative  medicine  remains  a  viable  and  exciting  goal  that  is  more  likely  to  succeed  
as  potential  pitfalls,  like  the  one  we  report  here,  are  identified  and  addressed.    
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Figure  1.  Acquisition  and  WES  of  140  hESC  lines.    
a,  Schematic  workflow  for  hESC  line  acquisition  and  sequencing.  b,c,  Of  the  307  hESC  lines  listed  on  the  
NIH   registry   at   the   time   of   this   study,   182   were   requested   and   114   could   be   obtained,   banked   (b),   and  
analyzed   by   WES   along   with   26   GMP-­prepared   cell   lines   (c).   d,   45   hESC   lines   were   excluded   due   to  
significant  restrictions  on  their  use.  e,  140  hESC  lines  from  19  institutions  were  banked  and/or  sequenced.  
Please   see   Table   S1   and   supplementary   methods   for   further   details.   f,   HESCs   were   minimally   cultured  
before  banking  and  sequencing.  g,  Cumulative  passage  number  of  hESCs  was  moderate.  h,  Mean  WES  
coverage  exceeded  60x  for  almost  all  sequenced  hESC  lines.  IRB,  institutional  review  board;;  MTA,  material  
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Figure  2.  Identification  of  recurrent,  cancer-­associated  TP53  mutations  in  hESCs.    
a,   Most   rare   heterozygous   genetic   variants   identified   by   WES   in   hESCs   variants   are   present   at  
approximately   balanced   (50/50)   allelic   proportions,   but   a   small   set   of   variants   is   present   at   lower   allelic  
fractions  (boxed  left).  b,  A  binomial  test  used  to  identify  variants  likely  to  be  mosaic  (P<0.01  for  lightest  red  
shading),   of   which   six   encode   missense   mutations   in   the   tumor   suppressor   gene   TP53   (Table   S3).   c,  
Genetic  variants   in   the  four  P53  codons  found  mutated   in  hESCs  are  rare   in  ExAC  (<0.0001).  d,  The  four  
P53  residues  found  mutated  in  hESCs  are  the  four  residues  most  commonly  mutated  in  human  tumors.  e,  
On   a   crystal   structure   of   P53   bound   to   DNA,   the   affected   residues   map   to   the   DNA   binding   domain,  
including  to  arginine  residues  that  directly  interact  with  DNA.  f)  The  residues  mutated  in  hESCs  disrupt  DNA  
binding  by  P53.    
  
  
Figure  3.  TP53  mutations  in  hESCs  are  mosaic  and  confer  strong  selective  advantage.    
a,   Droplet   digital   PCR   (ddPCR)   assay   schematic.  b,   A   representative   assay   exhibits   four   well-­separated  
clusters  of  droplets  that  contain  the  reference  allele  (C,  gray),  mutant  allele  (T,  red),  both  alleles  (T/C,  pink),  
or   neither   allele   (“no   amplicon”,   black).   The   fraction   of   hESCs   carrying   the  TP53   variant   is   estimated   by  
digitally  counting   the   four  species  of  droplets.  c,  Estimated   fraction  of  mutant  cells   (red)   in  affected  hESC  
lines.   d,   The   pronounced   increase   in   the   fraction   of   TP53   mutant   alleles   during   standard   hESC   culture  
suggests   that  TP53  mutation  confers  a  selective  advantage.  Error  bars  depict  SEM  and  numbers   indicate  
replicate  wells.  Note  the  second  wave  of  allele-­fraction  expansion  (after  P17)  for  WA26,  likely  involving  LOH.  
e,  Model  of  P53’s  role  in  inhibiting  both  cancer  formation  and  hPSC  reprogramming,  as  well  as  self-­renewal  
in  both  cell  types.  
     
Figure   4.   A   substantial   fraction   of   hPSCs   in   published   RNA   sequencing   studies   harbor   TP53  
mutations.    
a,b,c,  Published  RNA  sequencing  (RNAseq)  datasets   from  251  hESC  and  hiPSC  samples  (a),  contain  13  
unique  hESC  and  104  unique  hiPSC  lines  (b,c).  d,e,  TP53  mutations  are  observed  in  many  hESC  samples  
(40/135,   30%)   and   several   hiPSC   samples   (3/116,   3%)   (d),   together   affecting   7/117   (6%)   of   sequenced  
hPSC  lines  (e).  f,  Combined  RNAseq  and  WES  analysis  reveals  12/252  distinct  cell   lines  (5%)  affected  by  
15  TP53  mutations  (Table  S3),  three  of  which  (WA01,  WA09,  WIBR3)  showed  TP53  mutations  only  certain  
RNAseq  studies.  g,  22  samples  of  WA01  from  three  studies  carried  out  by  one  laboratory  carried  an  R181H  
mutation  (allelic  fraction  in  parentheses).  h,  The  commonly  used  WA09  cell  lines  carried  four  distinct  TP53  
mutations  observed  in  three  different  groups,  indicating  that  these  mutations  arose  independently  in  culture.  
i,  WIBR3  with  wild-­type  TP53   underwent  gene  editing  and  acquired  a  TP53  mutation  present   in  100%  of  
alleles,  indicating  likely  fixation  on  a  mutation  on  one  allele  and  a  LOH  on  the  other  allele;;  these  mutations  
did   prevent   teratoma   formation   or   gut   differentiation.   j,   WA09   carrying   a   fixed   TP53   mutation   could   be  
differentiated   to   neuroectodermal   cells.   k,   The  TP53   mutant   allelic   fraction   increased   over   the   course   of  
Cyt49   differentiation   to   pancreatic   polyhormonal   cells,   suggesting   a   persistent   selective   advantage   in  
differentiating   cells.   l,m,   Model   of   TP53   mutation   enrichment   by   selective   advantage   during   hPSC  
maintenance  (l)  or  during  clonal  bottlenecks  that  occur  during  gene  editing  or  inefficient  passaging  (m).    
     
MATERIALS  AND  METHODS  
  
hESC  acquisition  
As   a   source   of   hESCs   for   this   study,   we   focused   on   those   that   had   been  
voluntarily  listed  by  research  institutions  on  the  registry  of  hESC  lines  maintained  by  the  
US   National   Institutes   of   Health   (NIH)  
(http://grants.nih.gov/stem_cells/registry/current.htm).  As  of   July  8,  2015,  a   total  of  307  
hESC   lines  were   listed  on   this   registry.  Of   these,  we  requested  viable   frozen  stocks  of  
the   182   lines   annotated   to   be   available   for   distribution   and   to   lack   known   karyotypic  
abnormalities  or  disease-­causing  mutations.  During  our  effort   to  obtain   these  cell   lines,  
we   found   that   45   were   subject   to   overly   restrictive   material   transfer   agreements   that  
precluded  their  use  in  our  studies  and  11  could  not  be  readily  obtained  as  frozen  stocks  
due   to   differences   in   human   subjects   research   regulations   between   the   U.S.   and   the  
U.K.  Nine  cell  lines  were  unavailable  upon  request  or  were  overly  difficult  to  import,  and  
three  could  not  be  cultured  despite  repeated  attempts.  Further  details  on  the  availability  
of  cell  lines  can  be  found  in  Table  S1.  
  
hESC  culture  
Different   laboratories   employ   different   methods   to   culture   hESCs,   raising   the  
question   of   how   best   to   thaw   and   culture   the   cell   lines   we   obtained   from   multiple  
sources.  Traditionally,  hESCs  are  maintained  on  gelatinized  plates  and  co-­cultured  with  
replication  incompetent  mouse  embryonic  fibroblast  (MEF)  feeder  cells   in  tissue  culture  
medium   containing   knockout   serum   replacement   (KOSR).  More   recently,   hESCs  have  
been   shown   to   grow  well   on   a   substrate   of   cell   line-­derived   basal  membrane   proteins  
known  by  the  trade  names  of  Matrigel  (BD  Biosciences)  or  Geltrex  (Life  Technologies),  
in  mTeSR129,  E830,  or  similar  in  the  absence  of  feeder  cells.  In  previous  work,  we  found  
that   a  medium  containing  an  equal   volume  of  KOSR-­based  hESC  medium   (KSR)  and  
mTeSR1  (STEMCELL  Technologies)  (KSR:mTeSR1)  robustly  supports  the  pluripotency  
of   hESCs   undergoing   antibiotic   selection   during   the   course   of   gene   targeting  
experiments   under   feeder-­free   conditions31.   To   minimize   stress   to   hESCs   previously  
cultured  and  frozen  under  diverse  conditions,  cell   lines  were  thawed  in  the  presence  of  
10   µM   Y-­27632   (DNSK   International)   into   two   wells   of   a   6-­well   plate,   one   of   which  
contained   KSR:mTeSR1   on   a   substrate   of   Matrigel,   and   the   other   containing   KOSR-­
based  hESC  medium  on  a  monolayer  of  irradiated  MEFs.  After  24  hours,  Y-­27632  was  
removed  and  cells  were  fed  daily  with  the  aforementioned  media  in  the  absence  of  any  
antibiotics.  All   cultures  were   tested   for   the   presence  of  mycoplasma  and   cultured   in   a  
humidified  37°C  tissue  culture  incubator  in  the  presence  of  5%  CO2  and  20%  O2.    
Colonies   of   cells  with   hESC  morphology   and  with   a   diameter   of   approximately  
400-­1000  micrometers  were  transferred  into  MEFcm:mTeSR  medium  containing  10  µM  
Y-­27632  on  a   substrate   of  Matrigel   by  manual   picking  under   a   dissecting  microscope.  
Cells   with   differentiated   morphology   were   removed   from   plates   by   aspiration   during  
feeding.   Once   cultures   consisting   of   cells   with   homogeneous   pluripotent   stem   cell  
morphology  had  been  established,  they  were  passaged  by  brief  (2-­10  minute)  incubation  
in   0.5   mM   EDTA   in   PBS   followed   by   gentle   trituration   in   MEFcm:mTeSR   medium  
containing   10   µM   Y-­27632   and   re-­plating.   Once   cultures   had   reached   approximately  
90%   confluence   in   one  well   of   a   6  well   plate,   they  were   passaged  with   ETDA   onto   a  
Matrigel-­coated   10   cm   plate.   Upon   reaching   approximately   90%   confluence,   cell   lines  
were   dissociated  with  EDTA  as   described   above   and  banked   for   later   use   in   identical  
cryovials   containing   approximately   3   million   cells   each   in   cryoprotective   medium  
containing   50%  MEFcm:mTeSR,   10   µM  Y-­27632,   10%  DMSO,   and   40%   fetal   bovine  
serum  (HyClone).  A  subset  of  hESC  lines  (Table  S1)  were  passaged  enzymatically  with  
TrypLE  Express  (Life  Technologies),  expanded  onto  two  15  cm  plates,  and  frozen  down  
in  25  cryovials.    
  
Whole  exome  sequencing  and  genotyping  
Cell   pellets   of   approximately   1-­5   million   cells   were   generated   from   banked  
cryovials   of   research-­grade   hESC   lines,   or   were   obtained   directly   from   institutions  
providing  GMP-­grade  hESC  lines.  Cell  pellets  were  digested  overnight  at  50°C  in  500  µl  
lysis  buffer  containing  100  µg/ml  proteinase  K   (Roche),  10  mM  Tris   (pH  8.0),  200  mM  
NaCl,  5%  w/v  SDS,  10  mM  EDTA,  followed  by  Phenol:Chloroform  precipitation,  ethanol  
washes,   and   resuspension   in   10   mM   Tris   buffer   (pH   8.0).   Genomic   DNA   was   then  
transferred   to   the   Genomics   Platform   at   the   Broad   Institute   of   MIT   and   Harvard   for  
Illumina   Nextera   library   preparation,   quality   control,   and   sequencing   on   the   Illumina  
HiSeq  2500  platform.  Sequencing  reads  (150  bp,  paired-­end)  were  aligned  to  the  hg19  
reference  genome  using  the  BWA  alignment  program.  Genotypes  from  WES  data  for  the  
cell   lines  were  computed  using  best  practices   from  GATK  software32  compiled  July  31,  
2015.  Sequencing  quality  and  coverage  were  analyzed  using  Picard  tool  metrics.  Cross  
sample  contamination  was  estimated  using  VerifyBamID  (v1.1.2)33.  Data  from  each  cell  
line   was   independently   processed   with   the   HaplotypeCaller   walker   and   further  
aggregated   with   the   CombineGVCFs   and   GenotypeGVCFs   walkers   to   generate   a  
combined   variant   call   format   (VCF)   file.  Genotyped   sites  were   finally   filtered  using   the  
ApplyRecalibration  walker.  
To  determine  whether  lines  with  or  without  acquired  TP53  mutations  show  other  
chromosomal   aberrations   or   smaller   regional   changes   in   copy   number,   additional  
genotyping  of  the  140  hESC  lines  was  performed  using  a  custom  high  density  SNP  array  
(“Human  Psych  array”)  that  contains  more  than  half  a  million  SNPs  across  the  genome.  
CNVs   larger   than   500   kb   were   identified   using   the   PennCNV   (v1.0.0)34   tool  
(penncnv.openbioinformatics.org).  All  CNVs  were  manually   reviewed  and  are  shown   in  
Table  S6.    
  
Mosaic  variant  analysis  
   To   identify   candidate   mosaic   variants,   a   table   of   heterozygous   variants   was  
generated  from  the  VCF  (Table  S2).  To  limit  the  frequency  of  false  positive  calls  due  to  
sequencing  artifacts  and  PCR  errors,  variants  were   included   if   they  had  a  variant   read  
depth   (DP)   of   at   least   10,   if   they   were   either   flagged   as   a   “PASS”   site   or   were   not  
reported   in   the  Exome  Aggregation  Consortium’s   (ExAC)  database11,   and   if   they  were  
not   located   in   regions   of   the   genome   with   low   sequence   complexity,   common   large  
insertions   and   segmental   duplications,   as   described   by   Genovese   and   colleagues5.  
Multiallelic  sites  were  split,   left-­aligned,  and  normalized.  The   resulting   list  of  2.1  million  
“high-­quality   heterozygous   variants”   was   further   refined   to   include   sites   that   were  
covered  by  at   least  60  unique  reads  and  had  a  high  confidence  variant  score  (“PASS”)  
as   ascertained   by   GATK’s   Variant   Quality   Score   Recalibration   software   (840,222  
variants).   To   exclude   common   inherited   variants   we   selected   variants   present   in   less  
than  0.01%  of  the  (ExAC)  control  population  and  restricted  our  analysis  to  only  singleton  
or  doubleton  variants  (9490  variants  present  in  1-­2  of  the  140  samples).  Coverage  was  
calculated   by   summing   reference   and   alternate   allele   counts   for   each   variant.   Allelic  
fraction   (AF)   was   calculated   by   dividing   the   alternate   allele   count   by   the   total   read  
coverage  (both  alleles)  of  the  site.  
   Although  the  allelic  fraction  of   inherited  heterozygous  variants   is  expected  to  be  
50%,   reference   capture   bias   (a   tendency   of   hybrid   selection   to   capture   the   reference  
allele  more  efficiently  than  alternative  alleles)  causes  the  actual  expected  allele  fraction  
for  SNPs  and   indels   to  be  closer   to  45%  and  35%   respectively5.  To  account   for   these  
technical   biases,   we   used   a   binomial   test   with   a   null   model   centered   at   45%   allelic  
fraction  for  inherited  SNPs  and  35%  for  inherited  indels.  Variants  for  which  this  binomial  
test  was  nominally  significant  (P  <  0.01)  were  deemed  to  be  candidate  mosaic  variants.  
The  nominal  P-­value  threshold  of  0.01  was  chosen  as  an  inclusive  threshold  in  order  to    
screen  sensitively  for  potentially  mosaic  variants,  at  the  expense  of  also  capturing  false  
positives  for  which  low  allelic  fractions  represented  statistical  sampling  fluctuations.  For  
this   reason,  we  considered   it   important   to   further  evaluate  putative  mosaic   variants  by  
independent   molecular   methods   that   deeply   sample   alleles   at   the   nominated   sites  
(Figure  3).    A  much  more  stringent  computational  screen  based  on  a  P-­value  threshold  
of  10-­7   identified   three  of   the  six  TP53  variants,  and  TP53  was  also   the  only  gene  with  
multiple  putatively  mosaic  variants  in  this  screen.    
We  also  identified  all  high  quality  heterozygous  variants  that  passed  the  inclusive  
statistical  threshold  of  (P<0.01)  in  our  binomial  test  and  could  potentially  be  mosaic  
(n=36,396).  These  data  are  included  in  Table  S2.  	  
   Variant  annotation  was  performed  using  SnpEff  with  GRCh37.75  Ensembl  gene  
models.   Variants   with   moderate   impact   were   classified   as   damaging   by   a   consensus  
model  based  on  seven  in  silico  prediction  algorithms35.    
  
Assessment  of  TP53  mutation  frequency  in  cancer    
We  turned  to  the  ExAC  database11  that  complies  the  whole  exome  sequences  of  
over   60,000   individuals   to   assess   the   frequency   at  which   the   amino   acid   residues  we  
observed   to   be  mutated   in   some   hESCs  were   affected   in   the   general   population.  We  
then   consulted   the   COSMIC  
(http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53)12,  
ICGC  (https://cbioportal.gdc.cancer.gov/cbioportal/)13,   and   IARC   P53  
(http://p53.iarc.fr/TP53SomaticMutations.aspx)14   databases   and   plotted   the   percent   of  
tumors  carrying  a  mutation  in  each  codon  (Fig.  2d,  Fig.  S2b).  
  
Molecular  modeling  of  P53  protein  
To   visualize   the   spatial   location   of   the   amino   acid   residues   affected   by   TP53  
mutations   observed   in   hESCs   by   WES   on   the   P53   protein,   we   downloaded   the   1.9  
Angstrom   X-­ray   diffraction   based   structure   file   from   the   Research   Collaboratory   for  
Structural   Bioinformatics   Protein   Data   Bank   (file   3KMD)   and   visualised   the   secondary  
structure   of   a   P53   monomer   complexed   to   DNA   as   a   ribbon   diagram.   DNA   was  
illustrated   as   a   space-­filling   model.   Affected   residues   were   indicated   as   space-­filling  
model  superimposed  on  the  ribbon  diagram  of  P53  and  highlighted  in  blue  (wild-­type)  or  
red  (mutated)  without  consideration  of  how  the  mutations  might  affect  the  secondary  or  
tertiary  structure  of  the  protein.    
  
Measurement  of  TP53  variant  allele  fraction  by  ddPCR    
We  assayed   the  allelic   fraction  of   the   four  distinct  TP53  mutations   identified  by  
WES   (Table  S3)   in   the  140  hESC   lines  by  droplet  digital  PCR   (ddPCR).  Each  ddPCR  
analysis   incorporated   a  custom  TaqMan  assay   (IDT).   Assays  were   designed   with  
Primer3Plus  and  consisted  of  a  primer  pair  and  a  5’  fluorescently  labeled  probe  (HEX  or  
FAM)  with  3’  quencher  (Iowa  Black  with  Zen)  for  either  the  control  (reference)  or  mutant  
(alternative)  base   for  each   identified  P53  variant.  Primer  and  probe  sequences  used   in  
this  assay  are  given  in  Table  S4.  Genomic  DNA  from  each  hESC  line  was  analyzed  by  
ddPCR  according  to  the  manufacturer’s  protocol  (BioRad).  The  frequency  of  each  allele  
for   a   given   sample   was   estimated   first   by   Poisson   correction   of   the   endpoint  
fluorescence   reads21.   These   corrected   counts   were   then   converted   to   fractional  
abundance  estimates  of  the  mutant  allele  and  multiplied  by  two  to  determine  the  fraction  
of  cells  carrying  the  variant  allele.    
  
Longitudinal  hESC  culture  and  calculation  of  TP53  mutation  expansion  
To  assess  how  the  allelic   fraction  of  TP53  mutations  might  change  over   time   in  
culture,  hESC  lines  CHB11  (passage  22  or  25),  WA26  (passage  13  or  15),  and  ESI035  
(passage   36   in   two   separate   experiments)   were   serially   passaged   in   mTeSR1  media  
(STEMCELL   Technologies)   at   a   density   of   approximately   30,000   cells/cm2   in   the  
presence   of   10   µM   Y-­27632.   Cells   were   fed   daily   with   mTeSR1   and   passaged   with  
Accutase   (Innovative   Cell   Technologies   Inc.)   at   approximately   90%   confluence.   To  
monitor  changes   in  allelic   fractions,  genomic  DNA  from  cells  at   the   indicated  passages  
were  analyzed  by  ddPCR.  To  calculate  the  relative  expansion  rate  of  mutant  relative  to  
wild-­type  cells,  we  applied  the  following  formula:  
  	   𝑔 = ln𝑅& − ln 𝑅(𝑇& − 𝑇( 	  	  
where  R0   is   defined   as   the   ratio   of   (variant   positive   cells)/(variant   negative   cells)   after  
some  number  of  starting  passages  and  R1  and  R2   represent   the  aforementioned  ratios  
measured   on   the   same   sample   at   T1   and   T2>T1   passages   respectively.   From   this  
equation,   the  estimation  of  variant  positive  cells  after   t  passages   from  starting   ratio  R0  
can  be  defined  as  	   𝑅*𝑒,- 	  	  
Note   that   this   equation   estimates   the   relative   growth   rate   of   cells   carrying   the   variant  
allele  with  a   round  of  passaging  as  unit  of   time,  with  both   relative  survival  and  growth  
being  incorporated.  These  data  are  included  in  Table  S5.  For  the  subsequent  calculation  
of   the   earliest   passage   at   which   these  mutations  might   have   become   detectable,   the  
detection   thresholds   (R0)   for  WES  and  ddPCR  was  assumed   to  be  0.1   (10/100   reads)  
and  0.001  (1  per  1000  droplets),  respectively.  
  
RNA  sequencing  analysis  
In  order   to   identify  P53  mutations   in  hPSCs,  we  analyzed  256  publicly  available  
high-­throughput   RNA   sequencing   samples   of   hPSCs   from   the   SRA   database  
(http://www.ncbi.nlm.nih.gov/sra)36.  Data  accession  numbers  for  SRA  (and  GEO,  where  
applicable)   are   provided   in  Table  S7.  Five   of   these  256   samples  were   not   considered  
further   as   they   were   from   single   cells   rather   than   cell   lines.   Following   sequence  
alignment   to   the   hg19   reference   genome  with   Tophat237,   single   nucleotides   divergent  
from  the  reference  genome  were  identified  using  GATK  HaplotypeCaller32.  As  sufficient  
sequencing-­depth  is  required  to  deduce  sequence  mutation,  a  threshold  of  25  reads  per  
nucleotide   was   set.   Under   this   criterion,   43   samples   (40   hESC   and   3   hiPSC)   had   a  
missense  mutation   in  TP53.  10  of   the  40  hESC  samples   (WA09)  carried   two  separate  
mutations   (Table  S7).  Upon   the   identification   of   cell   lines   carrying  mutant   reads,  RNA  
sequencing   data   from   studies   containing   differentiated   samples   were   included   for  
analysis.      
  
Loss  of  heterozygosity  analysis  
In   order   to   evaluate  TP53  alleles,   we   assessed   the   level   of   polymorphism   by  
calculating   the   ratio   between   the   minor   and   major   alleles   across   chromosome   17.   In  
order  to  minimize  sequencing  noise  and  errors,  we  included  SNPs  covered  by  more  than  
10  reads  and  that  are  located  in  the  dbSNP  build  142  database38.  The  resulted  wig  files  
were   then   plotted   using   Integrative   Genomics   Viewer   (IGV)39   (Fig.   S4).   In   order   to  
quantify  the  difference  in  polymorphism  between  samples,  we  converted  the  wig  files  to  
BigWig  using  UCSC  Genome  Browser  utilities40  and  summed  the  allelic   ratios  between  
the  distal  part  of   the  short  arm  of  chromosome  17   (17p),   the  proximal  side  of   this  arm  
and  the  long  arm  of  chromosome  17  (17q).  The  allelic  ratio  sum  was  then  divided  by  the  
region's   length  (bp),  which  resulted   in   the  proportion  of  SNPs,   followed  by  one-­sided  Z  
score  test  for  two  population  proportion  to  compare  between  the  chromosome  17  areas  
within  each  sample.    While  most  samples  with  mutations  in  TP53  showed  a  comparable,  
non-­significant   rate   of   polymorphic   sites   along   the   chromosome,  WIBR3   samples  with  
H193R   mutations   and  WA09   samples   with   both   P151S   and   R248Q   mutations   had   a  
significantly  different  proportion   (p<0.001)  of  polymorphic  sites,   in   the  distal  part  of   the  
short   arm  of   the   chromosome   (first   16x106  base   pairs),   including  TP53  site.  Unlike   the  
three  mutant  WIBR3  samples,  the  wild-­type  WIBR3  sample  had  a  normal  distribution  of  
polymorphic  sites  with  no  significant  difference  between  the  short  and  long  arms.     
SUPPLEMENTARY  FIGURES  AND  LEGENDS  
  
Figure  S1.  Replicates  of   cell   competition  assays  carried  out   at   earlier   starting  passages.  Note   that  
while   the  mutant  allelic   fractions   for   lines  CHB11  and  WA26  approach   fixation,   that   the   fraction  of  mutant  
cells   unexpectedly   decreases   for   ESI035   over   several   passages,   indicating   a   potential   selective  
disadvantage  that  co-­segregates  with  the  TP53  mutation  in  this  experiment.  The  number  of  replicate  wells  is  































































Figure  S2.  Summary  of  all  observed  P53  mutations.  
a-­b,  Graphical  representation  of  each  of  the  9  mutated  bases  in  P53  observed  across  the  252  whole  exome  
sequenced  (WES)  and  RNA  sequenced  (RNAseq)  hPSC  lines  depicting  their  allele   frequency   in  ExAC  (a)  
and  the  incidence  with  which  the  relevant  codons  are  mutated  in  human  cancer  (b).  c,  The  15  instances  of  
these  mutations  in  12  distinct  cell  lines  is  represented  along  with  whether  the  mutation  was  seen  by  WES  or  
RNAseq.    Although  the  M237I  event  is  seen  in  two  distinct  iPSC  lines,  it  is  conservatively  counted  here  as  a  









































































Figure  S3.  Analysis  of  loss  of  heterozygosity  in  RNA  sequencing  samples.    
a,  Polymorphic  sites  on  chromosome  17  in  different  hPSCs  with  mutations  in  TP53.  WIBR3  cells  with  H193R  
mutation  and  H9  cells  with  both  P151S  and  R248Q  mutations  show  less  polymorphism  in  the  distal  part  of  
chromosome   17p   compared   to   the   proximal   part   of   17p   and   17q.   *samples   with   less   than   25   reads.  b,  
Summation  of  the  polymorphic  sites  in  the  distal  part  of  chromosome  17p  compared  to  the  proximal  part  of  
17p  and  17q,  divided  by  the  overall  frequency  of  polymorphic  sites  along  chromosome  17.  WIBR3  cells  with  
H193R  mutation  and  H9  cells  with  both  P151S  and  R248Q  mutations  have  a  significantly  different  proportion  
between   the   two   parts   of   the   chromosome,   implying   loss   of   heterozygosity   (LOH).   ***p   <   0.001.   c,   A  
schematic   representation  of   possible  allele   states  of  TP53   in   cultured  hPSCs  with  all   observed  mutations  
depicted.   Depending   on   the   percentage   of   mutant   reads   in   a   culture,   one   can   deduce   if   the   culture   is  




Figure  S4.  Culture  and  passaging  method  employed  for  samples  bearing  P53  mutations.  
a,  P53  mutations  were  observed   in  hPSCs  grown   in  a  broad  array  of  culture  media   including  home-­made  
medium  supplemented  with  knockout  serum  replacement  (KOSR),  and  defined,  commercial  media  such  as  
E8.  b,  Similar  numbers  of  P53  mutations  were  observed  from  cells  grown  with  feeder  cells  or  under  feeder-­
free   conditions.   c,   Since   passaging   hPSCs   can   introduce   stresses   or   clonal   bottlenecks,   we   examined  
whether   P53   mutations   were   consistently   seen   when   a   particular   passaging   method   was   used,   but   we  
observed  a  wide  variety  of  passaging  methods  associated  with  these  mutations.  Note  that  the  interpretation  
of  these  data  are  complicated  by  the  fact  that  the  culture  methods  employed  in  the  final  published  study  may  
not  reflect  the  previous  culture  history  of  that  cell   line,  which  may  have  previously  passed  through  multiple  
laboratories,  as  well  as  by   the   lack  of  detail  about  culture  methods  present   in  some  published  studies.  d,  
The  addition  of  supplements  such  as  rock  inhibitor  at  passages  does  not  appear  to  be  sufficient  to  prevent  
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SUPPLEMENTARY  TABLE  LEGENDS  
  
Table  S1.  Considered  and  whole  exome  sequenced  hESC  lines.    
Tab   1.   We   considered   hESC   lines   for   WES   if   they   were   listed   on   the   NIH   Human  
Embryonic  Stem  Cell  Registry  (http://grants.nih.gov/stem_cells/registry/current.htm)  or  if  
they   were   prepared   under   GMP   conditions.   Cell   lines   were   typically   excluded   from  
consideration   if   they   were   unavailable   for   distribution   or   contained   known   karyotypic  
abnormalities   in   more   than   10%   of   analyzed   cells   or   disease-­causing   mutations  
identified   by  PGD.  Cell   lines  with  MTAs   that   restricted   our   ability   to  work  with   the   cell  
lines,   that   could   not   be   recovered   upon   thawing,   or   proved   to   be   unavailable   upon  
request   were   also   excluded.   Passage   number   at   the   time   of   request,   the   number   of  
passages  and  time  in  culture  from  thaw  to  passaging,  and  the  passaging  method,  media,  
and   substrate,   are   provided,   as   is   mean   sequencing   coverage   and   %   cross   sample  
contaminated   per   cell   line.  GMP,   good  manufacturing   practice;;  MTA,  material   transfer  
agreement;;  PGD,   pre-­implantation   genetic   diagnosis;;  WES,  whole   exome   sequencing.  
Tab   2.  Summary  of   number  of   cells   considered  and  sequenced,   including   reasons   for  
exclusion.  These  data  are  presented  graphically  in  Figure  1b-­e.  
  
Table  S2.  Identification  of  candidate  mosaic  variants  present  in  sequenced  hESCs.    
Tab   1.   Filters   used   to   identify   likely  mosaic   variants   among   all   heterozygous   variants  
present   among   the   sequenced   exomes   of   140   hESCs.   Tab   2.   List   of   263   candidate  
mosaic   variants   passing   quality   control   filters   and   present   no   more   than   two   times  
among  the  140  sequenced  hESC  lines.  Variants  are  arranged  by  chromosome  position  
and  annotated  by  likely  functional  impact  and  frequency  in  the  general  population  (ExAC  
AC).  Tab  3.  Variants  from  the  list  in  Tab  2  predicted  to  have  either  a  high  or  damaging  
impact   on   gene   function   based   on   a   consensus   of   7   bioinformatic   algorithms.   See  
Materials  and  Methods  for  further  details.  Tab  4.  In  addition  to  mosaic  variants  identified  
using   these  stringent   filters,  we  provide  an   inclusive   list   of  all   high  confidence  somatic  
variants   (n=36,396)   that   pass   the   binomial   test   with   a   P   value   of   <0.01.   SNP,   single  
nucleotide   polymorphism;;   CHROM,   chromosome   number;;   POS,   genomic   position  
(hg19);;  REF,  reference  allele;;  ALT,  alternate  allele;;  HESC,  human  embryonic  stem  cell  
line;;  REFC,   count   of   reference   alleles;;  ALTC,   count   of   alternate   alleles;;   FILTER,   high  
confidence  variant  score;;  EXACAC,  allele  count   in   the  Exome  Aggregation  Consortium  
(ExAC)   database;;   IMPACT,   predicted   effect   of   mutation;;   HESCAC,   allele   count   in  
hESCs;;   TOTALC,   REFC+ALTC;;   AF,   allelic   faction   (ALTC/TOTALC);;   P,   P   value   for  
binomial  test  on  allelic  fraction.    
  
Table   S3.   Characteristics   of   TP53   mutations   identified   in   hESCs   by   WES   and  
RNAseq.    
Tab  1.  Summary  of  all  15  instances  of  TP53  mutations  observed  by  WES  and  RNAseq  
with  details  of  read  depth,  allelic  fraction,  P  value,  reference,  and  culture  method.  Note  
that   all   observed   mutations   are   frequently   seen   in   human   cancer,   and   that   most  
mutations  have  evidence  of  mosaicism,   indicating   that   they  were   likely  culture-­derived.  
bFGF,  basic  fibroblast  growth  factor  (FGF2);;  COSMIC,  Catalogue  of  Somatic  Mutations  
in   Cancer   (http://cancer.sanger.ac.uk/cosmic);;   ExAC,   Exome   Aggregation   Consortium  
(http://exac.broadinstitute.org/);;   Freq.,   frequency;;   GMP,   good   manufacturing   practice,  
IARC,   International   Agency   for   Research   on   Cancer   (http://p53.iarc.fr/);;   ICGC,  
International   Cancer   Genome   Consortium   (http://icgc.org/);;   MEF,   mouse   embryonic  
fibroblast;;   Seq.,   sequencing;;   SNL,  SNL  mouse   fibroblast   feeder   cell   line;;  WES,  whole  
exome   sequencing.   Errors   denote   SEM.   Tab   2.   Breakdown   of   the   incidence   of   P53  
mutations  by  culture  media,  substrate,  and  passaging  method.    
Table   S4.   Primer   and   probe   sequences   used   for   ddPCR-­based   determination   of  
P53  variant  allele  frequency.    
  
Table   S5.   Calculation   of   selective   advantage   conferred   by   three   distinct   TP53  
variants.    
The   allelic   fraction   of  TP53   variants  was  measured   at   several   passages   by   ddPCR   in  
hESCs   cultured   under   standard   conditions.   Replicate   experiments   per   passage   are  
shown  in  grey,  and  average  values  are  shown  in  black.  The  observed  increase  in  allelic  
frequency  of  each  of   the  variants  across   time   in  culture   is  consistent  with  a  substantial  
growth   or   survival   advantage   in   all   but   one   instance.   See   Materials   and   Methods   for  
details  on  ddPCR  and  the  calculation  of  the  effect  per  passage.    
  
Table  S6.   Large   copy  number   variants   in   hESCs   identified  by   the  Human  Psych  
array.    
Tab   1.      Summary   of   hESC   lines   with   large   copy   number   variants   (>500kb)   as  
ascertained   by   SNP   array   analysis.   Two   of   the   five   cell   lines   with   acquired   TP53  
mutations  harbored  large  structural  alternations  (HUES71  and  MShef10).  Five  separate  
cell   lines   (CSES25,   ESI051,  MShef3,   UM78-­1   and  WA21)   had   an   amplification   at   the  
pericentromeric  region  of  chromosome  20  (Chr20q11.21).  Tab  2.  Complete  list  of   large  
deletions  or  duplications  (>500kb)  identified  across  the  140  hESC  lines.  
  
Table  S7.  Identification  of  TP53  mutations  in  hPSCs  by  RNA  sequencing  and  WES  
Tab  1.  List  of  all  RNA  sequenced  samples  from  hPSCs.  Five  of  these  samples  (cell2-­7)  
were   removed   since   they   were   from   single   stem   cells   rather   than   cell   lines.   Tab   2.  
Summary  of   the  number  of  samples  and  studies  generated   from  each  cell   line.  Tab  3.  
List   of   all   samples   harboring   TP53   mutations,   their   chromosomal   location,   and   the  
relevant  study.  Tab  4.  Summary  of  all  affected  cell  lines  and  studies.  Tab  5.  Summary  of  
affected   samples,   cell   lines,   and   number   of  mutations   seen   in   hESCs   and   hiPSCs   by  
WES  and  RNAseq.       
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